Latent Tuberculosis Infection in Bone Marrow Transplant Recipients
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Hematopoietic Stem Cell Transplant Recipients|
- development of tuberculosis [ Time Frame: after transplantation ] [ Designated as safety issue: Yes ]
- all cause mortality [ Time Frame: after transplantation ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||January 2010|
|Study Completion Date:||June 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
|QFT (+) vs QFT (-)|
All adult bone marrow transplant recipients admitted to Asan Medical Center will be enrolled.
Quantiferon-Gold In-Tube assay will be performed.
Isoniazid prophylaxis will be given only to patients with clinical risk factors (i.e. recent contact with active pulmonary TB patient or inadequate treatment history with abnormal CXR). However, isoniazid prophylaxis will be not given based on positive TST or positive Quantiferon-Gold In-Tube assay.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01021124
|Korea, Republic of|
|Asan Medical Center|
|Seoul, Korea, Republic of, 138-736|
|Principal Investigator:||Sung-Han Kim, MD||Asan Medical Center|